EGX-B
≈ 2 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
EGX-B is a serotonin 5-HT 2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders. It acts as a agonist of the serotonin 5-HT 2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT 2A receptor over the serotonin 5-HT 2B receptor, is much more potent as a serotonin 5-HT 2A receptor agonist than psilocin, and produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. The drug is being developed by atai Life Sciences and EntheogeniX Biosciences. As of December 2023, it is in the preclinical research stage of development.
EGX-B is a serotonin 5-HT 2A receptor agonist and putative serotonergic psychedelic which is under development for the treatment of depressive disorders. It acts as a agonist of the serotonin 5-HT 2A receptor, shows high selectivity (>100-fold) for the serotonin 5-HT 2A receptor over the serotonin 5-HT 2B receptor, is much more potent as a serotonin 5-HT 2A receptor agonist than psilocin, and produces the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. The drug is being developed by atai Life Sciences and EntheogeniX Biosciences. As of December 2023, it is in the preclinical research stage of development.
See also
List of investigational hallucinogens and entactogens List of investigational antidepressants
References
External links
Data from our novel EGX series shows translational antidepressant-like effects, similar to those seen with psilocybin - atai Life Sciences (November 21, 2023) - LinkedIn
Text derived from https://en.wikipedia.org/w/index.php?oldid=1372018889 under CC BY-SA 4.0; modifications have been made.